Mechanisms of HCV-induced liver cancer: What did we learn from in vitro and animal studies?

Cancer Letters

Volumn 345, Issue 2, 2014, Pages 210-215

  Rusyn, Ivan ^a   Lemon, Stanley M ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Hepatitis C virus; Liver; Mechanisms; Models

Indexed keywords

CHIMPANZEE; DISEASE MODEL; FATTY LIVER; GENETIC ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TRANSGENIC MOUSE;

ANIMALIA; HEPATITIS C VIRUS;

CANCER; HEPATITIS C VIRUS; LIVER; MECHANISMS; MODELS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, VIRAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84896722341     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.06.028     Document Type: Review

References (85)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics CA Cancer. J. Clin. 2011, 61:69-90.
2. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Benbrahim-Tallaa L., Guha N., Freeman C., Galichet L., Cogliano V. WHO international agency for research on cancer monographs working group, a review of human carcinogens - Part B: biological agents. Lancet Oncol. 2009, 10:321-322.
3. de Martel C., Ferlay J., Franceschi S., Vignat J., Bray F., Forman D., Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012, 13:607-615.
4. El-Serag H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011, 365:1118-1127.
5. Lemon S.M., McGivern D.R. Is hepatitis C virus carcinogenic?. Gastroenterology 2012, 142:1274-1278.
6. Averhoff F.M., Glass N., Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin. Infect. Dis. 2012, 55(Suppl 1):S10-S15.
7. El Khoury A.C., Klimack W.K., Wallace C., Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J. Viral. Hepat. 2012, 19:153-160.
8. Welsch C., Jesudian A., Zeuzem S., Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012, 61(Suppl 1):i36-i46.
9. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
10. Bukh J. Animal models for the study of hepatitis C virus infection and related liver disease. Gastroenterology 2012, 142:1279-1287. e1273.
11. Munakata T., Nakamura M., Liang Y., Li K., Lemon S.M. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc. Natl. Acad. Sci. USA 2005, 102:18159-18164.
12. Walters K.A., Syder A.J., Lederer S.L., Diamond D.L., Paeper B., Rice C.M., Katze M.G. Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes. PLoS Pathog. 2009, 5:e1000269.
13. McGivern D.R., Lemon S.M. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011, 30:1969-1983.
14. Li Y., Zhang Q., Liu Y., Luo Z., Kang L., Qu J., Liu W., Xia X., Liu Y., Wu K., Wu J. Hepatitis C virus activates Bcl-2 and MMP-2 expression through multiple cellular signaling pathways. J. Virol. 2012, 86:12531-12543.
15. Singal A.K., Singh A., Jaganmohan S., Guturu P., Mummadi R., Kuo Y.F., Sood G.K. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin. Gastroenterol. Hepatol. 2010, 8:192-199.
16. Bruno S., Stroffolini T., Colombo M., Bollani S., Benvegnu L., Mazzella G., Ascione A., Santantonio T., Piccinino F., Andreone P., Mangia A., Gaeta G.B., Persico M., Fagiuoli S., Almasio P.L. DItalian association of the study of the liver sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007, 45:579-587.
17. Bigger C.B., Guerra B., Brasky K.M., Hubbard G., Beard M.R., Luxon B.A., Lemon S.M., Lanford R.E. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J. Virol. 2004, 78:13779-13792.
18. Liang Y., Shilagard T., Xiao S.Y., Snyder N., Lau D., Cicalese L., Weiss H., Vargas G., Lemon S.M. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 2009, 137:1448-1458.
19. Thio C.L., Thomas D.L. Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle. Gastroenterology 2010, 138:1240-1243.
20. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J.F., Furrer H., Gunthard H.F., Heim M., Hirschel B., Malinverni R., Moradpour D., Mullhaupt B., Witteck A., Beckmann J.S., Berg T., Bergmann S., Negro F., Telenti A., Bochud P.Y., Swiss Hepatitis C.C.S., Swiss H.I.V.C.S. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345. e1331-1337.
21. Feld J.J., Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005, 436:967-972.
22. Thursz M., Yallop R., Goldin R., Trepo C., Thomas H.C. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European network for cooperative research. Lancet 1999, 354:2119-2124.
23. Thio C.L., Goedert J.J., Mosbruger T., Vlahov D., Strathdee S.A., O'Brien S.J., Astemborski J., Thomas D.L. An analysis of tumor necrosis factor alpha gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection. Genes Immun. 2004, 5:294-300.
24. An P., Thio C.L., Kirk G.D., Donfield S., Goedert J.J., Winkler C.A. Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance. J. Infect. Dis. 2008, 198:1159-1165.
25. Huang Y., Yang H., Borg B.B., Su X., Rhodes S.L., Yang K., Tong X., Tang G., Howell C.D., Rosen H.R., Thio C.L., Thomas D.L., Alter H.J., Sapp R.K., Liang T.J. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 2007, 104:985-990.
26. Kumar V., Kato N., Urabe Y., Takahashi A., Muroyama R., Hosono N., Otsuka M., Tateishi R., Omata M., Nakagawa H., Koike K., Kamatani N., Kubo M., Nakamura Y., Matsuda K. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat. Genet. 2011, 43:455-458.
27. Hoshida Y., Fuchs B.C., Tanabe K.K. Genomic risk of hepatitis C-related hepatocellular carcinoma. J. Hepatol. 2012, 56:729-730.
28. Miki D., Ochi H., Hayes C.N., Abe H., Yoshima T., Aikata H., Ikeda K., Kumada H., Toyota J., Morizono T., Tsunoda T., Kubo M., Nakamura Y., Kamatani N., Chayama K. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat. Genet. 2011, 43:797-800.
29. Motomura T., Ono Y., Shirabe K., Fukuhara T., Konishi H., Mano Y., Toshima T., Yoshiya S., Muto J., Ikegami T., Yoshizumi T., Maehara Y. Neither MICA Nor DEPDC5 genetic polymorphisms correlate with hepatocellular carcinoma recurrence following hepatectomy. HPB Surg. 2012, 2012:185496.
30. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol. Rev. 2011, 239:99-108.
31. Lanford R.E., Lemon S.M., Walker C. The chimpanzee model of hepatitis C infections and small animal surrogates. Hepatitis C Antiviral Drug Discovery and Development 2011, 99-132. Horizons Scientific Press, Norwich, CT. Y. He, T. Tan (Eds.).
32. Meuleman P., Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral. Res. 2008, 80:231-238.
33. Akkina R. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 2013, 435:14-28.
34. Mercer D.F., Schiller D.E., Elliott J.F., Douglas D.N., Hao C., Rinfret A., Addison W.R., Fischer K.P., Churchill T.A., Lakey J.R., Tyrrell D.L., Kneteman N.M. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 2001, 7:927-933.
35. Bissig K.D., Wieland S.F., Tran P., Isogawa M., Le T.T., Chisari F.V., Verma I.M. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J. Clin. Invest. 2010, 120:924-930.
36. Bissig K.D., Le T.T., Woods N.B., Verma I.M. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc. Natl. Acad. Sci. USA 2007, 104:20507-20511.
37. Azuma H., Paulk N., Ranade A., Dorrell C., Al-Dhalimy M., Ellis E., Strom S., Kay M.A., Finegold M., Grompe M. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat. Biotechnol. 2007, 25:903-910.
38. Bility M.T., Zhang L., Washburn M.L., Curtis T.A., Kovalev G.I., Su L. Generation of a humanized mouse model with both human immune system and liver cells to model hepatitis C virus infection and liver immunopathogenesis. Nat. Protoc. 2012, 7:1608-1617.
39. Washburn M.L., Bility M.T., Zhang L., Kovalev G.I., Buntzman A., Frelinger J.A., Barry W., Ploss A., Rice C.M., Su L. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011, 140:1334-1344.
40. Moriya K., Fujie H., Shintani Y., Yotsuyanagi H., Tsutsumi T., Ishibashi K., Matsuura Y., Kimura S., Miyamura T., Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 1998, 4:1065-1067.
41. Lerat H., Honda M., Beard M.R., Loesch K., Sun J., Yang Y., Okuda M., Gosert R., Xiao S.Y., Weinman S.A., Lemon S.M. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002, 122:352-365.
42. Koike K., Moriya K., Matsuura Y. Animal models for hepatitis C and related liver disease. Hepatol. Res. 2010, 40:69-82.
43. Li Y., Tang Z.Y., Hou J.X. Hepatocellular carcinoma: insight from animal models. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:32-43.
44. Moriya K., Yotsuyanagi H., Shintani Y., Fujie H., Ishibashi K., Matsuura Y., Miyamura T., Koike K. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J. Gen. Virol. 1997, 78(Pt 7):1527-1531.
45. Korenaga M., Wang T., Li Y., Showalter L.A., Chan T., Sun J., Weinman S.A. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J. Biol. Chem. 2005, 280:37481-37488.
46. Moriya K., Nakagawa K., Santa T., Shintani Y., Fujie H., Miyoshi H., Tsutsumi T., Miyazawa T., Ishibashi K., Horie T., Imai K., Todoroki T., Kimura S., Koike K. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res. 2001, 61:4365-4370.
47. Liang T.J., Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004, 127:S62-S71.
48. Naas T., Ghorbani M., Alvarez-Maya I., Lapner M., Kothary R., De Repentigny Y., Gomes S., Babiuk L., Giulivi A., Soare C., Azizi A., Diaz-Mitoma F. Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J. Gen. Virol. 2005, 86:2185-2196.
49. Machida K., Tsukamoto H., Mkrtchyan H., Duan L., Dynnyk A., Liu H.M., Asahina K., Govindarajan S., Ray R., Ou J.H., Seki E., Deshaies R., Miyake K., Lai M.M. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc. Natl. Acad. Sci. USA 2009, 106:1548-1553.
50. Ahlen G., Nystrom J., Pult I., Frelin L., Hultgren C., Sallberg M. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J. Infect. Dis. 2005, 192:2112-2116.
51. Ahlen G., Sallberg M., Frelin L. Methods for monitoring gene gun-induced HBV- and HCV-specific immune responses in mouse models. Methods Mol. Biol. 2013, 940:239-267.
52. Hodges B.L., Scheule R.K. Hydrodynamic delivery of DNA. Exp. Opin. Biol. Ther. 2003, 3:911-918.
53. Pichard-Garcia L., Briolotti P., Larrey D., Sa-Cunha A., Suc B., Laporte S., Maurel P. Use of human hepatocytes to investigate HCV infection. Methods Mol. Biol. 2010, 640:447-462.
54. Fournier C., Sureau C., Coste J., Ducos J., Pageaux G., Larrey D., Domergue J., Maurel P. In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus. J. Gen. Virol. 1998, 79(Pt 10):2367-2374.
55. Buck M. Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS One 2008, 3:e2660.
56. Chong T.W., Smith R.L., Hughes M.G., Camden J., Rudy C.K., Evans H.L., Sawyer R.G., Pruett T.L. Primary human hepatocytes in spheroid formation to study hepatitis C infection. J. Surg. Res. 2006, 130:52-57.
57. Podevin P., Carpentier A., Pene V., Aoudjehane L., Carriere M., Zaidi S., Hernandez C., Calle V., Meritet J.F., Scatton O., Dreux M., Cosset F.L., Wakita T., Bartenschlager R., Demignot S., Conti F., Rosenberg A.R., Calmus Y. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology 2010, 139:1355-1364.
58. Molina S., Castet V., Fournier-Wirth C., Pichard-Garcia L., Avner R., Harats D., Roitelman J., Barbaras R., Graber P., Ghersa P., Smolarsky M., Funaro A., Malavasi F., Larrey D., Coste J., Fabre J.M., Sa-Cunha A., Maurel P. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J. Hepatol. 2007, 46:411-419.
59. Castet V., Fournier C., Soulier A., Brillet R., Coste J., Larrey D., Dhumeaux D., Maurel P., Pawlotsky J.M. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J. Virol. 2002, 76:8189-8199.
60. Andrus L., Marukian S., Jones C.T., Catanese M.T., Sheahan T.P., Schoggins J.W., Barry W.T., Dustin L.B., Trehan K., Ploss A., Bhatia S.N., Rice C.M. Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology 2011, 54:1901-1912.
61. Rau S.J., Hildt E., Himmelsbach K., Thimme R., Wakita T., Blum H.E., Fischer R. CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c-Jun N terminal kinase activation independent from the interferon pathway. Hepatology 2013, 57:23-36.
62. Bose S.K., Meyer K., Di Bisceglie A.M., Ray R.B., Ray R. Hepatitis C virus induces epithelial-mesenchymal transition in primary human hepatocytes. J. Virol. 2012, 86:13621-13628.
63. Ray R.B., Meyer K., Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 2000, 271:197-204.
64. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309:1577-1581.
65. Fukuhara T., Kambara H., Shiokawa M., Ono C., Katoh H., Morita E., Okuzaki D., Maehara Y., Koike K., Matsuura Y. Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus. J. Virol. 2012, 86:7918-7933.
66. Narbus C.M., Israelow B., Sourisseau M., Michta M.L., Hopcraft S.E., Zeiner G.M., Evans M.J. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J. Virol. 2011, 85:12087-12092.
67. Kambara H., Fukuhara T., Shiokawa M., Ono C., Ohara Y., Kamitani W., Matsuura Y. Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. J. Virol. 2012, 86:1382-1393.
68. Bukong T.N., Hou W., Kodys K., Szabo G. Ethanol facilitates hepatitis C virus replication via up-regulation of GW182 and heat shock protein 90 in human hepatoma cells. Hepatology 2013, 57:70-80.
69. Si-Tayeb K., Duclos-Vallee J.C., Petit M.A. Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study gets personal. J. Hepatol. 2012, 57:689-691.
70. Ndongo-Thiam N., Berthillon P., Errazuriz E., Bordes I., De Sequeira S., Trepo C., Petit M.A. Long-term propagation of serum hepatitis C virus (HCV) with production of enveloped HCV particles in human HepaRG hepatocytes. Hepatology 2011, 54:406-417.
71. D.T. Lau, A. Negash, J. Chen, N. Crochet, M. Sinha, Y. Zhang, J. Guedj, S. Holder, T. Saito, S.M. Lemon, B.A. Luxon, A.S. Perelson, M. Gale, Jr., Innate Immune Tolerance and the Role of Kupffer Cells in Differential Responses to Interferon Therapy Among Patients With HCV Genotype 1 Infection, Gastroenterology, 2012.
72. Sarasin-Filipowicz M., Wang X., Yan M., Duong F.H., Poli V., Hilton D.J., Zhang D.E., Heim M.H. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol. Cell. Biol. 2009, 29:4841-4851.
73. Chang J., Guo J.T., Jiang D., Guo H., Taylor J.M., Block T.M. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J. Virol. 2008, 82:8215-8223.
74. Lin L.T., Noyce R.S., Pham T.N., Wilson J.A., Sisson G.R., Michalak T.I., Mossman K.L., Richardson C.D. Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. J. Virol. 2010, 84:9170-9180.
75. D. Ploen, M.L. Hafirassou, K. Himmelsbach, D. Sauter, M.L. Biniossek, T.S. Weiss, T.F. Baumert, C. Schuster, E. Hildt, TIP47 plays a crucial role in the life cycle of hepatitis C virus. J. Hepatol., 2013.
76. Gastaminza P., Cheng G., Wieland S., Zhong J., Liao W., Chisari F.V. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 2008, 82:2120-2129.
77. Funakoshi N., Duret C., Pascussi J.M., Blanc P., Maurel P., Daujat-Chavanieu M., Gerbal-Chaloin S. Comparison of hepatic-like cell production from human embryonic stem cells and adult liver progenitor cells: CAR transduction activates a battery of detoxification genes. Stem Cell. Rev. 2011, 7:518-531.
78. Si-Tayeb K., Noto F.K., Nagaoka M., Li J., Battle M.A., Duris C., North P.E., Dalton S., Duncan S.A. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010, 51:297-305.
79. Schwartz R.E., Trehan K., Andrus L., Sheahan T.P., Ploss A., Duncan S.A., Rice C.M., Bhatia S.N. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc. Natl. Acad. Sci. USA 2012, 109:2544-2548.
80. Furutani T., Hino K., Okuda M., Gondo T., Nishina S., Kitase A., Korenaga M., Xiao S.Y., Weinman S.A., Lemon S.M., Sakaida I., Okita K. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006, 130:2087-2098.
81. Chouteau P., Defer N., Florimond A., Calderaro J., Higgs M., Gaudin A., Merour E., Dhumeaux D., Lerat H., Pawlotsky J.M. Hepatitis C virus (HCV) protein expression enhances hepatic fibrosis in HCV transgenic mice exposed to a fibrogenic agent. J. Hepatol. 2012, 57:499-507.
82. Uehara T., Kosyk O., Jeannot E., Bradford B.U., Tech K., Macdonald J.M., Boorman G.A., Chatterjee S., Mason R.P., Melnyk S.B., Tryndyak V.P., Pogribny I.P., Rusyn I. Acetaminophen-induced acute liver injury in HCV transgenic mice. Toxicol. Appl. Pharmacol. 2013, 266:224-232.
83. Jeannot E., Boorman G.A., Kosyk O., Bradford B.U., Shymoniak S., Tumurbaatar B., Weinman S.A., Melnyk S.B., Tryndyak V., Pogribny I.P., Rusyn I. Increased incidence of aflatoxin B1-induced liver tumors in hepatitis virus C transgenic mice. Int. J. Cancer 2012, 130:1347-1356.
84. Keasler V.V., Lerat H., Madden C.R., Finegold M.J., McGarvey M.J., Mohammed E.M., Forbes S.J., Lemon S.M., Hadsell D.L., Grona S.J., Hollinger F.B., Slagle B.L. Increased liver pathology in hepatitis C virus transgenic mice expressing the hepatitis B virus X protein. Virology 2006, 347:466-475.
85. Fox J.G., Feng Y., Theve E.J., Raczynski A.R., Fiala J.L., Doernte A.L., Williams M., McFaline J.L., Essigmann J.M., Schauer D.B., Tannenbaum S.R., Dedon P.C., Weinman S.A., Lemon S.M., Fry R.C., Rogers A.B. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 2010, 59:88-97.